RhumbLine Advisers’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
Other funds holding FULC
RhumbLine Advisers's FULC Position: Q3 2026 in Review
RhumbLine Advisers reduced its Fulcrum Therapeutics (FULC) stake by 2% in Q3 2026, selling an estimated $5.55K and leaving 71,964 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.
RhumbLine Advisers first reported a position in FULC in Q2 2020 and has held it in 26 quarters since. The position peaked at $852K in Q3 2021. 150 funds tracked by Wall St. Rank hold FULC as of Q3 2026.
- RhumbLine Advisers held 71,964 shares of Fulcrum Therapeutics worth $266K as of Q3 2026.
- RhumbLine Advisers sold 1,479 Fulcrum Therapeutics shares in Q3 2026, an estimated $5.55K.
- Fulcrum Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3106 holding.
- RhumbLine Advisers first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 26 quarters since.
- RhumbLine Advisers's Fulcrum Therapeutics position peaked at $852K in Q3 2021.
- 150 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.